- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Tetra Bio-Pharma Finishes Second Stage of Cannabis Trial
Tetra Bio-Pharma announced the completion of a phase two clinical trial of cannabis oil capsules treating uncontrolled chronic pain in cancer and non-cancer patients.
Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) announced the completion of a phase two clinical trial of cannabis oil capsules treating uncontrolled chronic pain in cancer and non-cancer patients.
As quoted in the press release:
Tetra Bio-Pharma, a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial of cannabis oil capsules. The trial evaluated the safety and efficacy of different doses and ratios of medical cannabis oil comprised of [tetrahydrocannabinol] THC and [cannabidiol] CBD, for the treatment of uncontrolled chronic pain in cancer and non-cancer patients.
The Phase 2 trial was conducted by Montreal-based Santé Cannabis, Quebec’s first clinical research organization specializing in cannabis and cannabinoids for medical purposes. Dr. Antonio Vigano, and his colleagues at Santé Cannabis, designed this study to obtain clinical data on the safety and potential efficacy of various cannabis oils used in the practice of medicine under the Cannabis regulations.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â